Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated‐Stat3 correlates with poor prognosis
Open Access
- 8 January 2010
- journal article
- research article
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 28 (7) , 971-978
Abstract
Stat3 expression in cancer may have important prognostic and therapeutic value, but there has been no reports correlating Stat3 expression with prognosis in patients with osteosarcoma. The goal of this study is to correlate patient prognosis with the expression of Stat3 in osteosarcoma tissue and determine the effectiveness of blocking this pathway in osteosarcoma cell lines by Stat3 inhibitor, CDDO‐Me. We examine the expression levels of Stat3 and pStat3 in osteosarcoma cell lines and primary tissues by Western blot analysis. We also evaluate the levels of pStat3 expression in osteosarcoma tissue microarray (TMA) by immunohistochemistry. We use clinical data to determine the impact of levels of Stat3 expression on patient prognosis. Finally, we evaluated the effect of CDDO‐Me on the inhibition of activated Stat3 pathway in osteosarcoma cell lines using MTT assay and Western blot analysis. Stat3 is observed to be activated in osteosarcoma tissues as well as in cultured cell lines. Overexpression of pStat3 is associated with poor prognosis. CDDO‐Me inhibits the growth of osteosarcoma cell lines and induces apoptosis as well. Our results suggest that Stat3 may be a prognostic indicator and potential therapeutic target for osteosarcoma. Blocking the pathway of Stat3 may lead to develop new therapeutic strategies against osteosarcoma. © 2010 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 28:971–978, 2010Keywords
This publication has 34 references indexed in Scilit:
- Characterization of STAT3 activation and expression in canine and human osteosarcomaBMC Cancer, 2009
- Osteosarcoma incidence and survival rates from 1973 to 2004Cancer, 2009
- CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cellsCancer Chemotherapy and Pharmacology, 2008
- Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cellsBMC Cancer, 2007
- The STAT3 oncogene as a predictive marker of drug resistanceTrends in Molecular Medicine, 2007
- STAT3 is activated in a subset of the Ewing sarcoma family of tumoursThe Journal of Pathology, 2006
- Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cellsProceedings of the National Academy of Sciences, 2005
- STAT proteins: From normal control of cellular events to tumorigenesisJournal of Cellular Physiology, 2003
- Stat3 as an OncogeneCell, 1999
- Common Musculoskeletal Tumors of Childhood and AdolescenceNew England Journal of Medicine, 1999